Breast cancer molecular subtypes categorized as HER2 (HR−/HER2+), triple-negative breast cancer (TNBC, HR−/HER2−), luminal A (hormone receptor (HR+)/human epidermal growth factor receptor 2 (HER2−), and luminal B (HR+/HER2+), have been displayed empirically in clinical value in conducting therapeutic plans [8]. Here, HR is linked to breast cancer.